Terminology and the Construction of Scientific Disciplines: The Case of Pharmacogenomics

Science, Technology and Human Values 28 (4):513-537 (2003)


This article explores the way in which social explanations underpin the names of particular disciplines. Taking the example of pharmacogenomics, it shows how this term has been constructed since it appeared in 1997, the differences and similarities between it and its precursor, pharmacogenetics, and the way in which commercial interests underpin this new term. Drawing on the idea of visions and the sociology of expectation, the article shows how different actors compete to have their preferred definitions of the term accepted by the world at large.

Download options


    Upload a copy of this work     Papers currently archived: 72,722

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library


Added to PP


6 months

Historical graph of downloads

Sorry, there are not enough data points to plot this chart.
How can I increase my downloads?

Citations of this work

The Promise of Pharmacogenetics: Assessing the Prospects for Disease and Patient Stratification.Andrew Smart & Paul Martin - 2006 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 37 (3):583-601.
The Bioeconomy as Political Project: A Polanyian Analysis.Vincenzo Pavone & Joanna Goven - 2015 - Science, Technology, and Human Values 40 (3):302-337.

View all 9 citations / Add more citations

Similar books and articles

Pharmacogenomics: Social, Ethical, and Clinical Dimensions.A. Hedgecoe - 2004 - Journal of Medical Ethics 30 (6):e6-e6.
Pharmacogenomics, Ethics, and Public Policy.Karen Peterson-Iyer - 2008 - Kennedy Institute of Ethics Journal 18 (1):pp. 35-56.
The Ethics of Pharmacogenomics.David Neil & Jillian Craigie - 2004 - Monash Bioethics Review 23 (2):9-20.
The Troubling Persistence of Race in Pharmacogenomics.Jonathan Kahn - 2012 - Journal of Law, Medicine and Ethics 40 (4):873-885.
Race, Pharmacogenomics, and Marketing: Putting BiDil in Context.Jonathan Kahn - 2006 - American Journal of Bioethics 6 (5):W1-W5.